Novartis: positive results for rare blood disorder drug.
(CercleFinance.com) - On Wednesday Novartis unveiled results of a long-term study supporting the positive safety and efficacy of Revolade in adults with chronic/persistent immune thrombocytopenia.
The results - published online in the "Blood" Journal - found that nearly 70% of patients managed to control their platelet counts without rescue therapy for prolonged periods, reducing the overall risk of bleeding.
For the record, Revolade has been approved in over 100 countries for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenic purpura who have had an inadequate response, or who are intolerant to other treatments.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The results - published online in the "Blood" Journal - found that nearly 70% of patients managed to control their platelet counts without rescue therapy for prolonged periods, reducing the overall risk of bleeding.
For the record, Revolade has been approved in over 100 countries for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenic purpura who have had an inadequate response, or who are intolerant to other treatments.
Copyright (c) 2017 CercleFinance.com. All rights reserved.